

Sterne Kessler
Goldstein Fox



Robert J. Kessler
Edward J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox
Robert J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox
Robert J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox

Jeffrey J. Kessler
Edward J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox
Robert J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox
Robert J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox

Kimberly A. Padden
Theodore A. Padden
Elizabeth A. Padden
Joseph A. Padden
David A. Padden
Robert A. Padden
Thomas J. Padden
Michael A. Padden
Michael A. Fox
Robert J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox
Robert J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox

Joanne M. Padden
Elizabeth A. Padden
Joseph A. Padden
David A. Padden
Robert A. Padden
Thomas J. Padden
Michael A. Padden
Michael A. Fox
Robert J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox
Robert J. Kessler
Joseph A. Goldstein
David A. Fox
Robert A. Stern
Thomas J. Goldstein
Michael A. Goldstein
Michael A. Fox

5300
Box 159

• Admitted to practice in Maryland
• Admitted to practice in Virginia
• Patent Agent
Federal Agencies

March 26, 2003

WRITER'S DIRECT NUMBER:

(202) 772-8589

INTERNET ADDRESS:

LARRYB@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Art Unit 1645

Re: U.S. Patent Application
Appl. No. 09/961,381; Filed: September 25, 2001
For: **Model for Neurodegenerative Diseases Involving Amyloid Accumulation**
Inventors: Lynch *et al.*
Our Ref: 1819.0040001/MAC/LBB

Sir:

Transmitted herewith for appropriate action are the following documents:

1. SKGF Cover Letter;
2. Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
3. Response to Notice to Comply and Submission of Sequence Listing;
4. Paper and disk copies of the Sequence Listing; and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.



Commissioner for Patents
March 26, 2003
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Lawrence B. Bugaisky
Attorney for Applicants
Registration No. 35,086

LBB/ybh
Enclosures

ODMA MHODMA SKGF_DCI:116508:1
SKGF Rev. 2 15 02 dew

UNITED STATES
PATENT AND
TRADEMARK OFFICECommissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09 961,381	09 25 2001	Gary Lynch	1819.0040001 MAC LBB

26111
STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 NEW YORK AVENUE, N.W., SUITE 600
WASHINGTON, DC 20005-3934

CONFIRMATION NO. 7154

FORMALITIES LETTER



OC000000009584380

Date Mailed: 03/03/2003

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES***Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE